AU Patent

AU653223B2 — Diltiazem formulation

Assigned to Aventis Pharmaceuticals Inc · Expires 1994-09-22 · 32y expired

What this patent protects

The present invention is directed to a diltiazem formulation suitable for one a day administration. The formulation contains a blend of diltiazem beads having two differing dissolution profiles. <IMAGE> <IMAGE>

USPTO Abstract

The present invention is directed to a diltiazem formulation suitable for one a day administration. The formulation contains a blend of diltiazem beads having two differing dissolution profiles. <IMAGE> <IMAGE>

Drugs covered by this patent

methylphenidate-hydrochloride (METHYLPHENIDATE HYDROCHLORIDE)

Patent Metadata

Patent number: AU653223B2
Jurisdiction: AU
Classification: —
Expires: 1994-09-22
Drug substance claim: No
Drug product claim: No
Assignee: Aventis Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.